Skip to main content
Year archive

CLARITY PHARMACEUTICALS LTD — 2023 filings

All 91 regulatory filings released by CLARITY PHARMACEUTICALS LTD (CU6) in 2023, sourced directly from the official regulator.

91 Filings
2023 Period
2023 filings (91)
Filing Released Lang
First patient dosed in Phase III prostate cancer trial 4 pages 371.8KB
Regulatory Filings
2023-12-21 English
Recruitment closes for a diagnostic Phase II trial in NETs 3 pages 287.0KB
Capital/Financing Update
2023-12-18 English
Change of Director's Interest Notice - Biggin 3 pages 968.4KB
Director's Dealing
2023-12-13 English
Change of Director's Interest Notice - Taylor 3 pages 946.6KB
Director's Dealing
2023-12-13 English
Notification regarding unquoted securities - CU6 10 pages 39.1KB
Share Issue/Capital Change
2023-12-12 English
Application for quotation of securities - CU6 8 pages 30.3KB
Share Issue/Capital Change
2023-11-30 English
Cleansing Notice 1 page 384.5KB
Regulatory Filings
2023-11-30 English
undetectable PSA level with Cu-67 SAR-bisPSMA 5 pages 1.4MB
Capital/Financing Update
2023-11-29 English
Phase III CLARIFY trial in prostate cancer commences 3 pages 373.4KB
Regulatory Filings
2023-11-29 English
Ceasing to be a substantial holder 3 pages 293.7KB
Major Shareholding Notification
2023-11-29 English
SECuRE theranostic prostate cancer trial progresses 4 pages 441.9KB
Regulatory Filings
2023-11-28 English
Application for quotation of securities - CU6 8 pages 30.5KB
Share Issue/Capital Change
2023-11-27 English
Application for quotation of securities - CU6 8 pages 30.5KB
Share Issue/Capital Change
2023-11-27 English
Cleansing Notice 1 page 610.0KB
Regulatory Filings
2023-11-27 English
2023 AGM Chair's Address to Shareholders 4 pages 245.4KB
AGM Information
2023-11-22 English
Managing Director's Presentation to AGM 27 pages 9.8MB
AGM Information
2023-11-22 English
2023 ESG Report 33 pages 8.9MB
Regulatory Filings
2023-11-22 English
Results of Meeting 1 page 68.9KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-22 English
Bell Potter Healthcare Conference Presentation 24 pages 7.0MB
Investor Presentation
2023-11-14 English
Recruitment target achieved for Phase II SAR-Bombesin trial 3 pages 271.8KB
Regulatory Filings
2023-11-06 English
2023 Appendix 4G 15 pages 1.1MB
Regulatory Filings
2023-11-02 English
Notification regarding unquoted securities - CU6 9 pages 33.7KB
Share Issue/Capital Change
2023-10-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 29 pages 9.4MB
Interim / Quarterly Report
2023-10-30 English
Presentation for Wilsons Drug and Device Conference 13 pages 4.7MB
Investor Presentation
2023-10-26 English
Clarity and PSI kick off SAR-bisPSMA Phase III 4 pages 627.4KB
Regulatory Filings
2023-10-25 English
Notice of Annual General Meeting/Proxy Form 25 pages 4.5MB
AGM Information
2023-10-19 English
Notification of cessation of securities - CU6 5 pages 25.7KB
Share Issue/Capital Change
2023-10-11 English
First patient treated with Cu-67 SAR-Bombesin 3 pages 256.7KB
Regulatory Filings
2023-10-02 English
Annual Report to shareholders 114 pages 15.6MB
Annual Report
2023-09-28 English
Corporate Governance Statement 18 pages 845.9KB
Governance Information
2023-09-28 English
BOP preliminary trial results presented at EANM 2023 4 pages 581.7KB
Regulatory Filings
2023-09-12 English
Company Presentation E&P Small Cap Healthcare Conference 32 pages 6.5MB
Investor Presentation
2023-09-12 English
Revised Change in substantial holding 2 pages 757.2KB
Regulatory Filings
2023-09-05 English
Ceasing to be a substantial holder 3 pages 218.7KB
Major Shareholding Notification
2023-09-04 English
Change in substantial holding 2 pages 723.9KB
Regulatory Filings
2023-09-04 English
Notification regarding unquoted securities - CU6 10 pages 38.8KB
Share Issue/Capital Change
2023-08-27 English
Application for quotation of securities - CU6 7 pages 28.6KB
Share Issue/Capital Change
2023-08-27 English
First PC participant treated at the highest dose level 4 pages 550.3KB
Regulatory Filings
2023-08-24 English
First neuroblastoma participant treated in highest cohort 3 pages 281.0KB
Regulatory Filings
2023-08-24 English
Preliminary Final Report 76 pages 5.5MB
Annual Report
2023-08-23 English
Release of Securities from Escrow 1 page 221.3KB
Regulatory Filings
2023-08-20 English
Theranostic prostate cancer trial advances to cohort 3 5 pages 580.9KB
Capital/Financing Update
2023-08-09 English
Clarity Bolsters Antibody Pre-Targeting with IP from MSK 3 pages 379.8KB
Regulatory Filings
2023-08-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 28 pages 6.1MB
Interim / Quarterly Report
2023-07-30 English
Final Cohort opens for CL04 Paediatric Neuroblastoma trial 2 pages 271.8KB
Capital/Financing Update
2023-07-25 English
Phase II SABRE prostate cancer trial reaches 50% recruitment 3 pages 469.5KB
Regulatory Filings
2023-07-23 English
Application for quotation of securities - CU6 8 pages 30.5KB
Share Issue/Capital Change
2023-07-05 English
Notification regarding unquoted securities - CU6 8 pages 31.0KB
Share Issue/Capital Change
2023-07-05 English
Cleansing Notice 1 page 609.8KB
Capital/Financing Update
2023-07-05 English
Change of Director's Interest Notice 3 pages 945.0KB
Director's Dealing
2023-07-05 English
Notification of cessation of securities - CU6 5 pages 25.3KB
Regulatory Filings
2023-07-04 English
Positive Guidance from FDA on Phase 3 Prostate Cancer Trial 3 pages 299.1KB
Capital/Financing Update
2023-07-03 English
Clarity Establishes US Center of Excellence for Research 2 pages 233.1KB
Capital/Financing Update
2023-06-27 English
Application for quotation of securities - CU6 8 pages 30.5KB
Share Issue/Capital Change
2023-06-27 English
Cleansing Notice 1 page 611.1KB
Regulatory Filings
2023-06-27 English
Northstar Achieves Key Production Milestones 4 pages 240.5KB
Capital/Financing Update
2023-06-26 English
COMBAT theranostic prostate cancer trial commences in the US 2 pages 354.0KB
Capital/Financing Update
2023-06-19 English
Application for quotation of securities - CU6 8 pages 30.5KB
Share Issue/Capital Change
2023-06-19 English
Cleansing Notice 1 page 551.0KB
Capital/Financing Update
2023-06-19 English
Clarity expands supply of Cu-64 for Phase III trials 2 pages 294.9KB
Capital/Financing Update
2023-06-13 English
Presentation at Jefferies Healthcare Conference 30 pages 3.0MB
Investor Presentation
2023-06-12 English
Recruitment complete for Phase II prostate cancer trial 4 pages 516.8KB
Regulatory Filings
2023-06-06 English
Clarity to present at ASCO and SNMMI 2023 Annual Meetings 2 pages 256.5KB
Regulatory Filings
2023-05-25 English
Notification regarding unquoted securities - CU6 9 pages 34.2KB
Share Issue/Capital Change
2023-05-24 English
Theranostic prostate cancer trial advances to cohort 2 4 pages 475.7KB
Capital/Financing Update
2023-05-23 English
Final Director's Interest Notice - O'Bryan Tear 3 pages 475.5KB
Director's Dealing
2023-05-15 English
Initial Director's Interest Notice 3 pages 346.1KB
Director's Dealing
2023-05-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 25 pages 18.7MB
Interim / Quarterly Report
2023-04-27 English
Clarity Receives $6.7 million R&D Tax Incentive Refund 1
Capital/Financing Update
2023-04-17 English
Notification of cessation of securities - CU6 6 pages 27.5KB
Regulatory Filings
2023-04-10 English
Notification regarding unquoted securities - CU6 9 pages 32.3KB
Share Issue/Capital Change
2023-04-04 English
Clarity update on NorthStar copper-67 production 2 pages 203.8KB
Capital/Financing Update
2023-04-03 English
Application for quotation of securities - CU6 8 pages 29.8KB
Share Issue/Capital Change
2023-03-27 English
Cleansing Notice 1 page 256.4KB
Regulatory Filings
2023-03-27 English
Clarity Corporate Presentation 39 pages 4.4MB
Investor Presentation
2023-03-12 English
Clarity confirms no supply interruptions 3 pages 217.0KB
Regulatory Filings
2023-03-01 English
World leading expert in copper-67 joins Clarity SAB 2 pages 211.2KB
Board/Management Information
2023-02-28 English
Appendix 4D 2 pages 840.7KB
Interim / Quarterly Report
2023-02-27 English
Half Yearly Report and Accounts 45 pages 9.6MB
Interim / Quarterly Report
2023-02-27 English
Application for quotation of securities - CU6 8 pages 29.9KB
Share Issue/Capital Change
2023-02-20 English
Notification regarding unquoted securities - CU6 8 pages 30.4KB
Share Issue/Capital Change
2023-02-20 English
Cleansing Notice 1 page 256.5KB
Capital/Financing Update
2023-02-20 English
Change of Director's Interest Notice - Biggin 3 pages 321.9KB
Regulatory Filings
2023-02-20 English
50% recruitment milestone for NET diagnostic Phase II trial 2 pages 242.8KB
Regulatory Filings
2023-02-15 English
PROPELLER Trial Results 4 pages 1.0MB
Capital/Financing Update
2023-02-13 English
Ceasing to be a substantial holder 5 pages 843.9KB
Regulatory Filings
2023-02-12 English
Diagnostic prostate cancer trial reaches recruitment target 2 pages 227.0KB
Regulatory Filings
2023-02-08 English
Application for quotation of securities - CU6 8 pages 29.8KB
Share Issue/Capital Change
2023-02-01 English
Changes to Clarity Board of Directors 2 pages 208.5KB
Board/Management Information
2023-01-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 21 pages 6.3MB
Interim / Quarterly Report
2023-01-30 English
Notification regarding unquoted securities - CU6 9 pages 32.3KB
Share Issue/Capital Change
2023-01-29 English